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Methotrexate (MTX) is a folic acid analogue that inhibits DNA
synthesis by causing an acute intracellular deficiency of folate
coenzymes. It is used widely for the treatment of a variety of
tumours and non-neoplastic conditions (Allen et al, 1986).
Methotrexate-associated pulmonary damage was first reported
in 1969 and since then reports have suggested that this may
occur irrespective of age, indication for use, dose or route of
administration (Massin et al, 1990). However, the frequency of
administration may be important as patients receiving the drug
daily or weekly seem more prone to pulmonary damage than do
those receiving it less frequently (Ginsberg, 1982). Features
unique to the pulmonary syndrome caused by MTX are that
discontinuation of the drug is not always required for clinical
recovery and rechallenge with the drug may not result in recurrent
symptoms. While the prognosis for pulmonary damage associated
with MTX is favourable, alternative therapy may be needed
because of symptoms and/or deterioration of pulmonary function
(Gillespie et al, 1999).
The incidence of gestational trophoblastic disease (GTD) is
1.5 per 1000 live births. Approximately 5% of patients require
treatment for persistent disease. The majority of patients have
low-risk disease and can expect to be cured with chemotherapy. In
the treatment of low-risk GTD, a cyclical regimen of four doses of
MTX 50 mg is given intramuscularly on alternate days. Each
injection is followed 24 h later by folinic acid 7.5 mg orally. Each
cycle is followed by a 7-day treatment-free period. The majority of
low-risk patients are cured with this regimen (Bagshawe et al,
1989).
We have reviewed the serosal side-effects experienced by
patients treated with single-agent low-dose intramuscular MTX
for GTD between January 1988 and December 1995. We also
report a probable case of MTX-induced peritonitis.
MATERIALS AND METHODS
Between January 1988 and December 1995, 168 consecutive
women with low-risk persistent GTD were treated with low-dose
intramuscular MTX at this centre. Serosal toxicity of the treatment
was analysed. The diagnosis of these side-effects was based on
complaints of pleuritic or peritoneal pain. Pleurisy was identified
as characteristic chest pain with normal chest radiograph appear-
ance. Pneumonitis was defined as chest pain in the presence of an
abnormal chest X-ray. However, these side-effects may overlap
and symptoms may be associated with reduced transfer factor on
pulmonary function tests in the presence of a normal chest X-ray.
Differential diagnoses were excluded by clinical examinations and
relevant investigations.
Symptoms were graded into two categories: mild to moderate
and severe, based on the severity of the complaint. Mild to
moderate symptoms were defined as those resolving sponta-
neously or with analgesia. Those graded as having severe toxicity
were those with severe pain warranting admission to hospital if not
inpatients already. In most cases of severe pain a change in treat-
ment was required. Most patients fell into the category of mild to
moderate pain.
RESULTS
Forty-two patients (25%) treated with low-dose intramuscular
MTX for persistent GTD developed serosal symptoms. Of these,
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patients treated (Table 1); 31.4% of this group were smokers and
5.7% were ex-smokers. A total of 5.7% of patients experiencing
pleurisy had a history of asthma. No other significant past medical
history was identified.
The vast majority of cases of MTX-induced pleurisy were of
mild to moderate severity (83% of symptomatic patients). Three
patients had pulmonary tests performed at the outset of treatment.
Of these, one had a transfer factor of 8.5 before treatment and 7.0
afterwards (normal range 8.2–10.6), although she experienced
only mild symptoms. One patient had reduced transfer factor
throughout treatment (pre-treatment 6.7, post-treatment 6.2) This
was associated with mild symptoms during courses one and six
and severe chest pain during course five requiring admission but
no change in treatment. The third had normal transfer factor
throughout treatment and experienced mild chest pain during
course four.
One patient complained of mild pleuritic pain while undergoing
treatment but later developed pericarditis. Pneumonitis occurred in
three patients, one of whom experienced severe symptoms.
Pericarditis occurred in one patient and peritonitis in one. We
briefly report the five patients in the severe category.
Case report 1
A 23-year-old woman was treated with intramuscular MTX for
low-risk GTD because of a persistently elevated human chorionic
gondatrophin (hCG) and recurrent vaginal bleeding following two
evacuations of retained products of conception (ERPC). All other
staging investigations (full blood count, blood chemistry, chest
X-ray, ultrasound abdomen and pelvis and computerized tomog-
raphy (CT) scan of thorax) were normal as were an electro-
cardiogram (ECG), pulmonary function tests and transfer factor.
The temporal relationship of pleuritic chest pain to treatment
was noticed from the second cycle onwards and is represented in
Figure 1. She had no pain with the first cycle of treatment. The
pain was not associated with shortness of breath, cough or
haemoptysis. She was tachycardic but afebrile. Oxygen saturation
on air was 98%. Chest and cardiovascular examination were
normal. Chest X-ray, ECG and pulmonary function tests revealed
no abnormality. She was converted to second-line chemotherapy
and had no further symptoms.
Case report 2
A 28-year-old woman with persistent GTD following a complete
molar pregnancy was started on low-dose MTX after her serum
hCG failed to show the expected fall despite three ERPCs. An
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Table 1 Serosal symptoms in 168 patients on low-dose intramuscular
methotrexate between 1988 and 1995
Symptom Mild–moderate (%) Severe (%)
Pleurisy 34 (20.2%) 3 (1.8%)
Pericarditis 0 1
Pneumonitis 2 (1.2%) 1 (0.6%)
Peritonitis 0 1
3
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1
0
MTX
Severity of pain
Second line
chemotherapy
No further
symptoms
Days
135791 1 1 3 1 5 1 7 1 9 2 1 2 3 2 5 2 7 2 9 3 1 3 3 33 53 73 94 14 34 54 74 95 15 35 55 75 9
Figure 1 Temporal pattern of pleuritis (in relation to MTX) (days 1–59). Mild, moderate and severe represented as 1, 2 and 3 units respectively.ultrasound scan of the uterus was suggestive of persistent molar
disease. Investigations revealed no evidence of lung metastases.
She first complained of severe pleuritic pain in the second half of
the fourth cycle. This was not associated with cough, breathlesness
or haemoptysis. Clinical examination and investigations, including
ventilation/perfusion scan of the lungs, were normal. The pain
improved with pethidine and subsided on completion of the
course. As only one further course of treatment was due, it was
decided to continue with the above regimen under full analgesic
cover. She tolerated the last cycle well with mild chest pain.
Case report 3
A 25-year-old woman with persistent GTD after a complete molar
pregnancy was treated with intramuscular MTX because of rising
hCG. CT scan of the thorax revealed two pulmonary nodules – a
1 cm diameter nodule in left mid zone and a 5 mm nodule in right
paramediastinal region. The temporal pattern of pleuritic pain
during all cycles of MTX is indicated in Figure 2.
During the second cycle, she developed severe right-sided pleu-
ritic pain not associated with cough, breathlesness or haemoptysis.
Physical examination was normal. A clinical diagnosis of MTX-
induced pleurisy was made. A chest X-ray was normal. She was
treated with analgesia. Shortly into the third course, she was 
re-admitted with excruciating right-sided pleuritic chest pain.
Clinical examination and chest X-ray were again normal. In view
of the worsening severity of the chest pain, she was changed to
second line chemotherapy of which she received seven cycles
with no major untoward side-effects and no recurrence of her
symptoms.
Case report 4
A 22-year-old woman with complete molar pregnancy was treated
with low-dose MTX because her hCG remained elevated 2 months
after an ERPC. CT scan showed a single pulmonary nodule of 1.5
cm diameter. She tolerated the treatment with no major side-effects
until the seventh cycle when she complained of mild left-sided
pleuritic chest pain. The only abnormality on examination was a
pleural rub at the base of the left lung. Methotrexate-associated
pleurisy was diagnosed. She responded quickly to analgesia. No
further investigations were done at that stage. She received a total
of nine courses of methotrexate. Two months after completion of
treatment, she had recurrence of her chest symptoms associated
with breathlessness on exertion. Examination revealed no abnor-
mality but chest X-ray showed cardiomegaly and echocardiogram
revealed a large pericardial effusion. Her ECG was normal. 
Six hundred and fifty ml of clear fluid was aspirated from her
pericardial sac. Examination of the fluid was consistent with an
inflammatory exudate. Bacterial cultures, serial viral titres and
autoantibody screen were negative. Following pericardiocentesis,
her symptoms resolved and have not recurred to date.
Case report 5
A 27-year-old woman was admitted with persistent bleeding after
a second ERPC for complete molar pregnancy. Her hCG was
elevated at 62 515 iu l–1. Ultrasound scan of the abdomen and
pelvis revealed a bulky uterus consistent with persistent GTD. The
right ovary measured 3.4 ´ 4.5 cm and contained cystic and solid
areas. The left ovary was not visualized. CT scan of the thorax was
normal.
During the first cycle of treatment, she developed right-sided
abdominal pain which worsened during the next 3 days (Figure 3).
The pain was aggravated by movement and was associated with
tenderness and guarding. Bowel sounds were normal. Repeat ultra-
sound scan of abdomen and pelvis was unchanged. She was
managed conservatively with appropriate analgesia.
At the start of the next cycle, she felt well in herself and her
hCG had fallen to 15 839 iu l–1. In the latter part of the second
cycle, she was re-admitted with severe right-sided abdominal pain.
Physical signs were similar to those found during the first cycle of
treatment and further investigations including repeat ultrasound
abdomen were normal. She was managed conservatively with
intravenous fluid and analgesia.
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Figure 2 Temporal pattern of pleurisy (in relation to MTX) (days 1–40). Mild, moderate and severe represented as 1, 2 and 3 units respectively.In view of the severe abdominal pain which was related tempo-
rally to the MTX, she was changed to second-line therapy. There
were no further abdominal symptoms.
DISCUSSION
While MTX-induced pneumonitis is a well established clinical
entity, the aetiology and pathophysiology are poorly understood.
The syndrome of MTX pleural toxicity is usually that of pleuritic
pain with both a normal chest X-ray and ventilation perfusion
scan. X-ray changes, if present, are non-specific – the most
common abnormality being reticulonodular shadowing, usually
diffuse and symmetrical with basal predominance. Pulmonary
function tests may reveal reduced gas transfer and a restrictive
ventilatory defect (Forbat et al, 1995). The differential diagnosis in
these patients includes pneumonia, tumour lysis in those with
pulmonary metastases and pulmonary embolism. Clinical exami-
nation, chest X-ray, ECG and ventilation perfusion scan help in
excluding these possible causes.
The frequency of pulmonary/pleural complications in our
patients with gestational trophoblastic disease on low-dose
repeated courses of methotrexate is much higher (22%) than those
with other MTX regimens (5–12%) (Stover, 1992).
Patients with mild to moderate pleuritic pain are managed by
maintaining adequate hydration and simple analgesia. If this does
not provide adequate symptom relief stronger analgesia including
opiates are used. Non steroidal anti-inflammatory drugs are
avoided as they reduce renal excretion of MTX and so may
exacerbate the toxicity. 
The underlying pathophysiology is unclear. Akoun et al (1987)
studied three patients with the syndrome and reported the
synthesis of a leucocyte inhibitory factor by the peripheral blood
lymphocytes after incubation with MTX in a direct leucocyte
migration inhibition test. This response was not seen in the control
group nor in patients on treatment who did not develop the compli-
cation, suggesting that pleurisy and pneumonitis seen with MTX is
associated with a specific cellular immune response to the drug.
This hypothesis was supported by White et al (1989) who
performed bronchoalveolar lavage on six patients with MTX-
induced pneumonitis. They reported a significant increase in
number of cells, particularly lymphocytes, in the lavage fluid.
There was a predominance of helper T-cells and a relative defi-
ciency of suppressor T-cells. These changes were not seen in the
healthy control group or those on treatment with no chest symp-
toms. These findings suggest that MTX pneumonitis is an
immunologically mediated injury rather than a direct toxic effect.
Pleurisy and pneumonitis may, however, be due to different mech-
nisms although there may be an overlap. Mucosal toxicity has a
well recognized association with MTX and yet only 4.7% of
patients in this series developed mucositis. Methotrexate adminis-
tration over 8 days may damage dividing mucosal or serosal cells
with some selectivity for different sites.
Forbat et al (1995) suggested that a cellular immune response
might cause MTX-induced pericarditis based on the findings of
Case 4, although the authors indicated that the possibility of an
unrecognized viral infection or a reaction to an unsuspected
allergen could not be excluded.
No patients in this series developed long-term lung problems as
a result of this treatment. We report a possible case of MTX-
induced peritonitis. In this patient the other possible causes of
abdominal pain: uterine perforation by trophoblastic disease,
tumour necrosis, rupture of or bleed into an ovarian cyst, ovarian
cyst torsion, pelvic inflammatory disease, acute salpingitis and
other surgical/medical causes of abdominal pain were excluded as
best possible. We appreciate that there exists no definitive diag-
nostic tool to prove our assumption and that the evidence is
circumstantial. However, the temporal relationship between MTX
administration and the patient’s symptoms was consistent and
dramatic as was the absence of symptoms in subsequent non-MTX
treatments. It is therefore possible that the ‘peritoneal’ pain experi-
enced by our patient was caused by a mechanism similar to that of
the pneumonitis/pleurisy syndrome. Two other patients in our
series had similar (though milder) symptoms: in these patients also
we were unable to find another cause for the ‘peritoneal’ pain.
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Figure 3 Temporal pattern of peritonitis (in relation to MTX) (days 1–25). Mild, moderate and severe represented as 1, 2 and 3 units respectively.CONCLUSION
Serosal symptoms are a common complication of low-dose
repeated MTX administration, occurring in 25% of patients treated
for low-risk persistent GTD. The most common complaint is
pleurisy and in the majority of cases this is of mild to moderate
severity and does not require a change of treatment. Other serosal
surfaces can also be involved, including pericardium and peri-
toneum. The underlying pathophysiology is poorly understood but
severe symptoms usually respond to discontinuation of MTX and
substitution of second-line therapy.
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